Funds and ETFs Hangzhou Tigermed Consulting Co., Ltd
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
55.5 CNY | +3.54% | +1.46% | +0.96% |
Apr. 25 | Hangzhou Tigermed Consulting’s Profit Down 59% in Q1 | MT |
Apr. 25 | Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024 | CI |
ETFs positioned on Hangzhou Tigermed Consulting Co., Ltd
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 7 M€ | +5.21% | - | |
0.00% | 7 M€ | +0.11% | - | |
0.00% | 8 M€ | +0.71% | - | |
0.00% | 15 M€ | +12.74% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.96% | 5.98B | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- 300347 Stock
- Funds and ETFs Hangzhou Tigermed Consulting Co., Ltd